Evidence map›Paper›PMID 39993808›Full record

ArticleCancer genomics & proteomics

Methylation of ESRα Promoters in Benign Breast Tumors Could Be a Signature for Progression to Breast Cancer in African American Women.

Sylvia Dasi, Tammey J Naab, Bernard Kwabi-Addo, Victor Apprey, Desta Beyene, Robert L Dewitty, Steven Nagel, Robin Williams, Kelly Bolden, Andrea Hayes-Dixon and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sylvia DasiHoward University Cancer Center, Howard University, Washington, DC, U.S.A.
Tammey J NaabAthari Biosciences, Sterling, VA, U.S.A.
Bernard Kwabi-AddoDepartment of Biochemistry and Molecular Biology, Howard University College of Medicine, Howard University, Washington, DC, U.S.A.
Victor AppreyHoward University Cancer Center, Howard University, Washington, DC, U.S.A.
Desta BeyeneHoward University Cancer Center, Howard University, Washington, DC, U.S.A.
Robert L DewittyDepartment of Surgery, Howard University Hospital, Washington, DC, U.S.A.
Steven NagelDepartment of Surgery, Howard University Hospital, Washington, DC, U.S.A.
Robin WilliamsDepartment of Surgery, Howard University Hospital, Washington, DC, U.S.A.
Kelly BoldenDepartment of Surgery, Howard University Hospital, Washington, DC, U.S.A.
Andrea Hayes-DixonDepartment of Surgery, Howard University Hospital, Washington, DC, U.S.A.
Babak ShokraniDepartment of Pathology, Howard University Hospital, Washington, DC, U.S.A.
Delisha A StewartDepartment of Microbiology, Howard University College of Medicine, Howard University, Washington, DC, U.S.A.
Olakunle O KassimDepartment of Microbiology, Howard University College of Medicine, Howard University, Washington, DC, U.S.A.
Robert L Copeland *Department of Pharmacology, Howard University College of Medicine, Howard University, Washington, DC, U.S.A.
Yasmine M Kanaan *Howard University Cancer Center, Howard University, Washington, DC, U.S.A.; ymkanaan@howard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMethylation in the estrogen receptor alpha (ESRα) promoter is an epigenetic abnormality associated with breast cancer (BCa), whereas hypermethylation results in the loss of ER expression. MATERIALS AND

methodsPyrosequencing was used to investigate a potential link between aberrant methylation in the P0/P1 promoters of ESRα and the risk of progression of benign fibrocystic and fibroadenoma tumors to BCa.

resultsResults showed a significantly elevated level of DNA methylation in ESRα P1 promoter (

conclusionESRα P0 promoter hypermethylation may occur in the early stages of breast carcinogenesis, while P1 promoter methylation appears in later stages with a poor prognosis. Therefore, methylation of the ESRα promoter and other tumor-related genes could serve as a potential biomarker for predicting fibroadenoma progression risk to BCa.

Indexed as

Black or African AmericanBreast NeoplasmsDNA MethylationEstrogen Receptor alphaFibroadenomaPromoter Regions, GeneticAdultBiomarkers, TumorDisease ProgressionFemaleHumansMiddle AgedTumor Suppressor ProteinsBiomarkers, TumorESR1 protein, humanEstrogen Receptor alphaTumor Suppressor Proteinsbreast cancerDNA methylationestrogen receptor alphafibroadenoma

Identifiers

PMID39993808
PMCPMC11880923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.